Summary

Eligibility
for people ages 18 years and up (full criteria)
Dates
study started
completion around
Principal Investigator
by Jeffery L Saver, MD

Description

Summary

STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).

Official Title

STEP: StrokeNet Thrombectomy Endovascular Platform

Details

The StrokeNet Thrombectomy Endovascular Platform (STEP) is conducted within NIH StrokeNet at 38 comprehensive stroke centers across the US. The primary goal is to optimize all aspects of care of acute ischemic stroke patients with a large or a medium vessel occlusion. The platform trial operates under an overarching Master Protocol in an inferentially integrated framework. The platform trial is designed to support the studies of three broad categories of therapeutics: expansion of endovascular treatment (EVT) indications, innovative EVT devices and concomitant medical therapies, and novel pre- and early-hospital technologies and systems of care. As new interventions are put forth, they will be added to the Master Protocol as a new Domain or part of an existing Domain. STEP utilizes a flexible Bayesian design with frequent adaptive analyses to assess whether a given intervention is superior, inferior, or equivalent either within a Domain or for specific populations within the Domain.

Keywords

Ischemic Stroke, Endovascular thrombectomy with any FDA-approved category POL or NRY device, Medical Management

Eligibility

For people ages 18 years and up

STEP PLATFORM INCLUSION CRITERIA:

  1. Suspected diagnosis acute ischemic stroke
  2. Likely causative intracranial large or medium vessel occlusion

STEP PLATFORM EXCLUSION CRITERIA:

  1. Proven contraindication to endovascular thrombectomy
  2. Prisoners/incarcerated

DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:

Each domain may have additional eligibility criteria.

STEP EVT INDICATION EXPANSION DOMAIN INCLUSION CRITERIA:

  1. Age 18 years or older
  2. Pre-stroke modified Rankin Scale score 0-2
  3. Within 24 hours of last known well
  4. Has one of the following presentations:
    1. Low NIHSS Patient (must have both): i.) Mild presenting neurologic deficits - NIHSS 0-5 ii.) Occlusion of the intracranial Internal Carotid Artery (ICA) or M1 Middle Cerebral Artery (MCA)
    2. Medium/Distal Vessel Occlusion (must have all 3): i.) Lumen diameter >/= 0.75 ii.) Non-dominant/Co-dominant M2 or M3,4 or A1,2,3 or P1,2,3 iii.) Less than 50% core in the territory supplied by the occluded vessel as evident by hypodensity and loss of grey-white border on Non-contrast Computed Tomography (NCCT) or ADC <620 mm2/s on diffusion MRI or rCBF<30% on Computed Tomography Perfusion (CTP) after 6h of symptom onset.

STEP EVT INDICATION EXPANSION DOMAIN EXCLUSION CRITERIA:

  1. Clinical
    1. Presumed septic embolus; suspicion of bacterial endocarditis
    2. Seizure at stroke onset or between onset and enrollment
    3. Allergy to contrast material that precludes endovascular reperfusion therapy
    4. Intracranial occlusion suspected to be chronic, based on history and/or imaging
    5. Intracranial dissection, based on history and/or imaging
    6. Cerebral vasculitis, based on history and/or imaging
    7. Known pregnancy
    8. Known pre-existing medical, neurological or psychiatric disease that would confound the neurological or functional evaluations
    9. Known serious, advanced, or terminal illness or life expectancy less than 6 months in the investigator judgment
  2. Laboratory
    1. Known platelet count <100.000 uL
  3. Imaging
    1. Unfavorable vascular anatomy that limits access to the occluded artery precluding endovascular reperfusion therapy.
    2. Acute occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation)
    3. Significant mass effect with midline shift (>5mm)
    4. Evidence of intraaxial tumor (except small meningioma)
    5. Evidence of acute intracranial hemorrhage

Lead Scientist at UCLA

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Medical University of South Carolina
ID
NCT06289985
Study Type
Interventional
Participants
Expecting 2000 study participants
Last Updated